Deans' stroke musings: Tolerization to Brain and Vascular Antigens: Targeting Autoimmunity After Acute Brain Injuries and Preventing Stroke

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, November 16, 2013

Tolerization to Brain and Vascular Antigens: Targeting Autoimmunity After Acute Brain Injuries and Preventing Stroke

No idea what this means.
link.springer.com/chapter/10.1007/978-1-4614-8915-3_16#page-1

Purchase on Springer.com

$29.95 / €24.95 / £19.95*

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The immune response can contribute to the risk of stroke as well as to brain injury following stroke. Directed modulation of the immune response to attenuate risk or injury is thus a potential therapeutic strategy for treating stroke. Inducing a population of antigen-specific regulatory T cells is one such strategy and can be used to locally modulate the immune response to the organs in which the antigen is present, thereby limiting potential side effects. This chapter addresses the use of mucosal tolerance to both prevent and treat ischemic stroke.